Rethinking Our Use of CSFs in the Adjuvant Treatment of Women Who Have Estrogen Receptor Positive Cancers - a podcast by American Society of Clinical Oncology (ASCO)

When dose dense treatment was first described we were greatly enthusiastic for all women with breast cancer. As the experience has matured we now realize that the benefit is confined to women with ER negative cancers. We think it is time to question our use of CSFs and dose dense treatment in ER+ women based on 2 large trials and a conclusive meta-analysis.

Further episodes of Journal of Clinical Oncology (JCO) Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)